Ignite Creation Date:
2024-05-06 @ 7:18 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02504619
Status:
TERMINATED
Last Update Posted:
2019-06-26
First Post:
2015-01-21
Brief Title:
Allogeneic SCT of CordIn in Patients With Hemoglobinopathies
Sponsor:
Gamida Cell ltd
Organization:
Gamida Cell ltd
Study Overview
Official Title:
Allogeneic Stem Cell Transplantation of CordIn Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells in Patients With Hemoglobinopathies
Status:
TERMINATED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
lack of recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CordIn is a cryopreserved stemprogenitor cell-based product of purified CD133 cells composed of ex vivo expanded allogeneic UCB cells The overall study objectives are to evaluate the safety and efficacy of CordIn
Detailed Description:
CordIn is a cryopreserved stemprogenitor cell-based product of purified CD133 cells composed of ex vivo expanded allogeneic UCB cells
The trial ends when the last patient completes their last visit The overall study objectives are to evaluate the safety and efficacy of CordIn single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies sickle cell disease or thalassemia major following a preparative therapy
The trial ends when the last patient completes their last visit The overall study objectives are to evaluate the safety and efficacy of CordIn single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies sickle cell disease or thalassemia major following a preparative therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None